Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Unknown 3

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 6HER2 Positive Metastatic Breast Cancer 3Stomach Neoplasms 1Non-squamous NSCLC 1Non Small Cell Lung 1HER2-positive Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1HER2 Positive Gastric Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pyrotinib 3Capecitabine 3Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × HER2 Positive Metastatic Breast Cancer × pyrotinib × Clear all
NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
279 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡